박용욱 교수 연구실
article|
gold
·인용수 46
·2023
Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial
Joon Young Song, Won Suk Choi, Jung Yeon Heo, Eun Jin Kim, Jin Soo Lee, Dong Sik Jung, Shin‐Woo Kim, Kyung‐Hwa Park, Joong Sik Eom, Su Jin Jeong, Jacob Lee, Ki Tae Kwon, Hee Jung Choi, Jang Wook Sohn, Young Keun Kim, Byung Wook Yoo, In‐Jin Jang, Maria Z Rosario Capeding, François Roman, Thomas Breuer, Piotr J. Wysocki, Lauren Carter, Sushant Sahastrabuddhe, Manki Song, Naveena D’Cor, Hun Kim, Ji Hwa Ryu, Su Jeen Lee, Yong Wook Park, Hee Jin Cheong, Agathe Philippot, Francesca Solmi, Maria Angeles Ceregido, Byoung-Shik Shim, Sang Hwan Seo, Simone D'Souza, Patchara Thaisrivichai, Josefina Carlos, Edison Alberto, Sorachai Nitayaphan, Winai Ratanasuwan, Piroon Mootsikapun, Romanee Chaiwarith, Luong Chan Quang, Olena Karpenko, Tatiana Yurkiv, Vitalii Kutovyi, Angela Bartko, Olga Gyrina, Olga Barna, Mykhailo Pugach, Claire Thurlow, Simon Carson, Susan Smith, Mike Williams, Tiwini Hemi Senior, Tim Humphrey, Davitt Sheahan, Hokeun Park, Yoon Yeong Lee, Seung Gu Kang
IF 9.6EClinicalMedicine
초록
This work was supported, in whole or in part, by funding from CEPI and the Bill & Melinda Gates Foundation Investments INV-010680 and INV-006462. The Bill & Melinda Gates Foundation supported this project for the generation of IND-enabling data and CEPI supported this clinical study.
키워드
MedicineImmunogenicityCohortInterim analysisVaccinationInternal medicineSeroconversionRandomized controlled trialImmunologyAntibody